Sino Biopharm (HK.1177) released its 2022 ESG Report on the 28th. The report shows that the company fulfills its mission of "improving the quality and protecting the dignity of human life", actively undertakes social responsibilities, engages in social welfare, and effectively promotes a low-carbon transition. In 2022, the Group's total investment in public welfare amounted to RMB 66.648 million, and its total environmental investment exceeded RMB 100 million. In terms of green and sustainable development, it pioneered the "Sino Biopharmaceutical Carbon Neutrality Planning Project" within the industry, aiming to provide substantial support for the comprehensive achievement of China's dual carbon goals and the active response to climate change risks.

During this reporting period, the company strengthened the link between environmental performance and management performance, incorporating environmental performance into the performance appraisal scope for senior management of the Group and its member companies as a key performance indicator. In 2022, Sino Biopharm's total investment in environmental protection amounted to RMB 108.9758 million, with carbon dioxide emission intensity decreasing by 15.54% year-on-year; renewable energy use increased by 46.15% year-on-year; water resource use intensity decreased by 8.28% year-on-year; and hazardous waste emission intensity decreased by 3.43% year-on-year.

The report points out that for many years, Sino Biopharm, combining the characteristics of the pharmaceutical industry with its own resource advantages, has continuously contributed corporate strength to various charitable and public welfare aspects such as disaster relief, fighting epidemics, rural revitalization, and educational donations. In 2022, facing recurrent and multi-point outbreaks of the epidemic, the company actively responded to the national call. Member companies, while ensuring the health and safety of their employees, overcame numerous difficulties to actively resume work and production, ensuring product manufacturing and logistics supply. At the same time, the Group's member companies actively participated in the regulation of medical supplies by health departments. Through donating materials and participating in epidemic prevention, they fully engaged in the fight against the epidemic in their respective regions, standing together with the local people to overcome the difficulties.

Miss Theresa Tse, Chairwoman of the Board of Sino Biopharm, pointed out that the company will remain true to its original mission, act with kindness, carry on its national sentiment, and actively fulfill its corporate citizen responsibilities. It will seek health and well-being for more patients, develop together with employees and partners from all sectors, and stride forward on the path of pursuing the harmonious development of the company, employees, the environment, and society, with good ESG governance as the cornerstone.

Welcome to visit our official website to view the "Sino Biopharm 2022 Environmental, Social and Governance Report"